2026 Q1 -tulosraportti
44 päivää sitten
‧1 t 2 min
7,95 DKK/osake
Viimeisin osinko
4,10%Tuotto/v
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 190 | - | - | ||
| 135 | - | - | ||
| 126 | - | - | ||
| 479 | - | - | ||
| 420 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 5.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
2 t sitten2 t sittenPublisert 18.Juni-26: Name recognition and "familiarity" with Novo Nordiisk's oral Wegovy has contributed to its rapid uptake in its battle with Lilly's oral GLP-1 Foundayo, according to Spherix analyst Jim Hickey, who conducts monthly surveys with doctors who prescribe the treatments. See Fierce's story on Hickey's analysis: What’s been Novo Nordisk's secret weapon to turn the tables on Eli Lilly and win the current market battle over their oral GLP-1 obesity drugs? Name recognition. That's according to Jim Hickey, an analyst with Spherix Global Insights, who has studied the competition by surveying 50 primary care physicians (PCPs) and 50 endocrinologists in the United States, as well as writing monthly reports on the uptake of the drugs, both of which debuted on the market earlier this year. “It’s interesting to see how strongly Novo Nordisk has come out of the gate,” Hickey said in an interview with Fierce. “It’s a very strong launch from what we can see. That lines up with the data Novo Nordisk has shared. I think a big difference between the two really comes down to familiarity. We see the familiarity ratings for the Wegovy pill as being much stronger than what we can see for Foundayo.” Novo’s pill, launched in January, has the advantage of sharing its name with the company’s injected weight-loss drug, Wegovy, and both formats are derived from the same GLP-1 compound, semaglutide. Lilly’s Foundayo (orforglipron), launched in April, is an entirely new molecule that differs from the company’s injected GLP-1/GIP blockbuster, tirzepatide. In the U.S., the dual agonist is known as Zepbound for obesity and Mounjaro for Type 2 diabetes. Foundayo, on the other hand, is a single-target GLP-1 agonist like Novo's Wegovy pill. While many analysts have chalked up Novo’s early success to its first-to-market advantage, Hickey believes—based on feedback from doctors—that familiarity is more at play. There is a “comfort and knowledge,” with semaglutide that doesn’t exist with orforglipron, Hickey said. In the most recent weekly reporting period, oral Wegovy had attracted 159,000 prescriptions compared to 19,879 for Foundayo, according to IQVIA data. It was the 22nd week on the market for Wegovy, compared to the ninth week for Foundayo. Analysis of data using IQVIA prescription trends may be imperfect—however, failing to capture a significant number of telehealth referrals for the increasingly popular obesity pills, analysts have cautioned. Related ‘I’m a lot more optimistic today’: Mike Doustdar tells Fierce about pivotal first year as Novo Nordisk CEO Framed another way, Novo reported earlier this month that since the Wegovy pill's launch on Jan. 5, the tablet has garnered more than 3 million total prescriptions. The bulk of those scripts are from patients new to the GLP-1 class.- ·5 t sittenNow we are waiting for approval from EMA for pill sales in Europe! It is known that it will come 2-3 months after the recommendation from CHMP, and that recommendation came in mid-May 2026. So at the latest July/August the approval will come. Imagine if sales go like in the USA!!
·7 t sittenIt is, according to All the “experts”, a company with a lot of good upcoming products! But…but the market isn't on board with that! It's not just Novo that these “experts” see great opportunities in, but why do they keep up with all their prophecies, because it goes opposite to their predictions. Is it because they want to influence the market for their sponsors?·5 t sitten · MuokattuYou understand that they must report to the stock exchange and inform us owners if the data breach is of such a nature that the company is harmed or that sensitive personal data has been leaked? They do not consider the breach serious enough for that to be necessary. So just forget that information. It's been several days now. We are waiting for approval from EMA for pill sales in Europe! It is known that it will come 2-3 months after the recommendation from CHMP, and that recommendation came in mid-May 2026. So the approval will come by July/August at the latest. You'll get an ulcer if you worry that much, Kuni.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
44 päivää sitten
‧1 t 2 min
7,95 DKK/osake
Viimeisin osinko
4,10%Tuotto/v
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- 2 t sitten2 t sittenPublisert 18.Juni-26: Name recognition and "familiarity" with Novo Nordiisk's oral Wegovy has contributed to its rapid uptake in its battle with Lilly's oral GLP-1 Foundayo, according to Spherix analyst Jim Hickey, who conducts monthly surveys with doctors who prescribe the treatments. See Fierce's story on Hickey's analysis: What’s been Novo Nordisk's secret weapon to turn the tables on Eli Lilly and win the current market battle over their oral GLP-1 obesity drugs? Name recognition. That's according to Jim Hickey, an analyst with Spherix Global Insights, who has studied the competition by surveying 50 primary care physicians (PCPs) and 50 endocrinologists in the United States, as well as writing monthly reports on the uptake of the drugs, both of which debuted on the market earlier this year. “It’s interesting to see how strongly Novo Nordisk has come out of the gate,” Hickey said in an interview with Fierce. “It’s a very strong launch from what we can see. That lines up with the data Novo Nordisk has shared. I think a big difference between the two really comes down to familiarity. We see the familiarity ratings for the Wegovy pill as being much stronger than what we can see for Foundayo.” Novo’s pill, launched in January, has the advantage of sharing its name with the company’s injected weight-loss drug, Wegovy, and both formats are derived from the same GLP-1 compound, semaglutide. Lilly’s Foundayo (orforglipron), launched in April, is an entirely new molecule that differs from the company’s injected GLP-1/GIP blockbuster, tirzepatide. In the U.S., the dual agonist is known as Zepbound for obesity and Mounjaro for Type 2 diabetes. Foundayo, on the other hand, is a single-target GLP-1 agonist like Novo's Wegovy pill. While many analysts have chalked up Novo’s early success to its first-to-market advantage, Hickey believes—based on feedback from doctors—that familiarity is more at play. There is a “comfort and knowledge,” with semaglutide that doesn’t exist with orforglipron, Hickey said. In the most recent weekly reporting period, oral Wegovy had attracted 159,000 prescriptions compared to 19,879 for Foundayo, according to IQVIA data. It was the 22nd week on the market for Wegovy, compared to the ninth week for Foundayo. Analysis of data using IQVIA prescription trends may be imperfect—however, failing to capture a significant number of telehealth referrals for the increasingly popular obesity pills, analysts have cautioned. Related ‘I’m a lot more optimistic today’: Mike Doustdar tells Fierce about pivotal first year as Novo Nordisk CEO Framed another way, Novo reported earlier this month that since the Wegovy pill's launch on Jan. 5, the tablet has garnered more than 3 million total prescriptions. The bulk of those scripts are from patients new to the GLP-1 class.
- ·5 t sittenNow we are waiting for approval from EMA for pill sales in Europe! It is known that it will come 2-3 months after the recommendation from CHMP, and that recommendation came in mid-May 2026. So at the latest July/August the approval will come. Imagine if sales go like in the USA!!
- ·7 t sittenIt is, according to All the “experts”, a company with a lot of good upcoming products! But…but the market isn't on board with that! It's not just Novo that these “experts” see great opportunities in, but why do they keep up with all their prophecies, because it goes opposite to their predictions. Is it because they want to influence the market for their sponsors?·5 t sitten · MuokattuYou understand that they must report to the stock exchange and inform us owners if the data breach is of such a nature that the company is harmed or that sensitive personal data has been leaked? They do not consider the breach serious enough for that to be necessary. So just forget that information. It's been several days now. We are waiting for approval from EMA for pill sales in Europe! It is known that it will come 2-3 months after the recommendation from CHMP, and that recommendation came in mid-May 2026. So the approval will come by July/August at the latest. You'll get an ulcer if you worry that much, Kuni.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 190 | - | - | ||
| 135 | - | - | ||
| 126 | - | - | ||
| 479 | - | - | ||
| 420 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 5.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 |
2026 Q1 -tulosraportti
44 päivää sitten
‧1 t 2 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 5.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 |
7,95 DKK/osake
Viimeisin osinko
4,10%Tuotto/v
Foorumi
Liity keskusteluun Nordnet Socialissa
- 2 t sitten2 t sittenPublisert 18.Juni-26: Name recognition and "familiarity" with Novo Nordiisk's oral Wegovy has contributed to its rapid uptake in its battle with Lilly's oral GLP-1 Foundayo, according to Spherix analyst Jim Hickey, who conducts monthly surveys with doctors who prescribe the treatments. See Fierce's story on Hickey's analysis: What’s been Novo Nordisk's secret weapon to turn the tables on Eli Lilly and win the current market battle over their oral GLP-1 obesity drugs? Name recognition. That's according to Jim Hickey, an analyst with Spherix Global Insights, who has studied the competition by surveying 50 primary care physicians (PCPs) and 50 endocrinologists in the United States, as well as writing monthly reports on the uptake of the drugs, both of which debuted on the market earlier this year. “It’s interesting to see how strongly Novo Nordisk has come out of the gate,” Hickey said in an interview with Fierce. “It’s a very strong launch from what we can see. That lines up with the data Novo Nordisk has shared. I think a big difference between the two really comes down to familiarity. We see the familiarity ratings for the Wegovy pill as being much stronger than what we can see for Foundayo.” Novo’s pill, launched in January, has the advantage of sharing its name with the company’s injected weight-loss drug, Wegovy, and both formats are derived from the same GLP-1 compound, semaglutide. Lilly’s Foundayo (orforglipron), launched in April, is an entirely new molecule that differs from the company’s injected GLP-1/GIP blockbuster, tirzepatide. In the U.S., the dual agonist is known as Zepbound for obesity and Mounjaro for Type 2 diabetes. Foundayo, on the other hand, is a single-target GLP-1 agonist like Novo's Wegovy pill. While many analysts have chalked up Novo’s early success to its first-to-market advantage, Hickey believes—based on feedback from doctors—that familiarity is more at play. There is a “comfort and knowledge,” with semaglutide that doesn’t exist with orforglipron, Hickey said. In the most recent weekly reporting period, oral Wegovy had attracted 159,000 prescriptions compared to 19,879 for Foundayo, according to IQVIA data. It was the 22nd week on the market for Wegovy, compared to the ninth week for Foundayo. Analysis of data using IQVIA prescription trends may be imperfect—however, failing to capture a significant number of telehealth referrals for the increasingly popular obesity pills, analysts have cautioned. Related ‘I’m a lot more optimistic today’: Mike Doustdar tells Fierce about pivotal first year as Novo Nordisk CEO Framed another way, Novo reported earlier this month that since the Wegovy pill's launch on Jan. 5, the tablet has garnered more than 3 million total prescriptions. The bulk of those scripts are from patients new to the GLP-1 class.
- ·5 t sittenNow we are waiting for approval from EMA for pill sales in Europe! It is known that it will come 2-3 months after the recommendation from CHMP, and that recommendation came in mid-May 2026. So at the latest July/August the approval will come. Imagine if sales go like in the USA!!
- ·7 t sittenIt is, according to All the “experts”, a company with a lot of good upcoming products! But…but the market isn't on board with that! It's not just Novo that these “experts” see great opportunities in, but why do they keep up with all their prophecies, because it goes opposite to their predictions. Is it because they want to influence the market for their sponsors?·5 t sitten · MuokattuYou understand that they must report to the stock exchange and inform us owners if the data breach is of such a nature that the company is harmed or that sensitive personal data has been leaked? They do not consider the breach serious enough for that to be necessary. So just forget that information. It's been several days now. We are waiting for approval from EMA for pill sales in Europe! It is known that it will come 2-3 months after the recommendation from CHMP, and that recommendation came in mid-May 2026. So the approval will come by July/August at the latest. You'll get an ulcer if you worry that much, Kuni.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 190 | - | - | ||
| 135 | - | - | ||
| 126 | - | - | ||
| 479 | - | - | ||
| 420 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt